Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens

This is a multi-center, longitudinal observational study of adult human immunodeficiency virus (HIV) participants at academic and community-based practices in the United States who are switching from first-line to second-line therapy. The study's primary hypothesis is that HIV participants switching to raltegravir-based regimens will have better Medical Outcomes Study-HIV (MOS-HIV) Health Survey scores than participants switched to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based or protease inhibitor (PI)-based regimens.

Inclusion Criteria:

• Clinical diagnosis of HIV
• Switching antiretroviral regimen(s) for the first time at the start of the study

Exclusion Criteria:

• Currently pregnant
• Presence of active tuberculosis, Hepatitis B, and/or Hepatitis C and receiving treatment for the condition(s) during the study period
• Presence of active pneumonia or other signs of opportunistic infections at the start of the study
• Currently participating in a clinical trial